Exploratory study of biomarkers for therapeutic efficacy and immune-related adverse events of immune checkpoint inhibitors
Not Applicable
Recruiting
- Conditions
- All cancer types indicated for immune checkpoint inhibitor
- Registration Number
- JPRN-UMIN000043798
- Lead Sponsor
- Kumamoto University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 400
Inclusion Criteria
Not provided
Exclusion Criteria
The patient whom the researcher consider to be inappropriate for the study.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Identification of genetic factors associated with immune-related adverse events
- Secondary Outcome Measures
Name Time Method Identification of genetic factors associated with the therapeutic effects of immune checkpoint inhibitors
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What biomarkers correlate with therapeutic efficacy in immune checkpoint inhibitor trials for oncology?
How do PD-L1 expression levels and TMB influence immune-related adverse events in ICI-treated cancer patients?
What are the comparative effectiveness outcomes of immune checkpoint inhibitors versus standard-of-care in metastatic melanoma and NSCLC?
Which molecular signatures predict resistance to immune checkpoint inhibitors in solid tumors like breast and colorectal cancer?
What management strategies are used for irAEs in Kumamoto University's observational ICI biomarker study?